RedHill Biopharma (RDHL) Retained Earnings (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Retained Earnings data on file, last reported at -$413.8 million in Q4 2025.

• On a quarterly basis, Retained Earnings changed 0.25% year-over-year to -$413.8 million in Q4 2025; TTM through Dec 2025 was -$413.8 million, a 0.25% change from a year earlier, with the FY2025 full-year figure at -$413.8 million, changed 0.25% from the prior year.
• Retained Earnings for Q4 2025 stood at -$413.8 million, up from -$418.1 million in the prior quarter.
• Over the last five years, Retained Earnings for RDHL reached as high as -$302.3 million in Q1 2021 and fell as low as -$433.9 million in Q4 2022.
• Historically, Retained Earnings has averaged -$387.8 million across 5 years, with a median of -$397.2 million in 2022.
• Across the five-year window, Retained Earnings tumbled 35.82% in 2021 and rose 6.02% in 2023, its largest moves.
• Year by year, Retained Earnings stood at -$367.9 million in 2021, then dropped by 17.94% to -$433.9 million in 2022, then gained by 6.02% to -$407.7 million in 2023, then fell by 1.73% to -$414.8 million in 2024, then grew by 0.25% to -$413.8 million in 2025.
• Per Business Quant data, the three most recent Retained Earnings figures were -$413.8 million in Q4 2025, -$418.1 million in Q2 2025, and -$414.8 million in Q4 2024.